Clinical Trials Logo

Clinical Trial Summary

Patients with suspected BPDCN and meeting eligibility criteria will be enrolled in the study. First, BPDCN diagnosis will be confirmed by anatomic pathology (Dr Petrella T, Montreal) and cytologic plus immunophenotyping analysis (Pr Garnache Ottou F, UMR1098 BESANCON). Patients will then receive three 21 days cycles of a combination of chemotherapy (Ida/Metho/L-asp/Dex), followed by an evaluation. Patients with complete response (CR) or complete response with incomplete bone marrow recovery (CRi) will undergo an allo- or auto-SCT and those who are not eligible to the transplantation will have successive 28 days cycles of chemotherapy (Metho/L-asp/Dex). Patients who did not respond to the treatment will be treated by physicians. All patients will be followed for 24 months.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
  • Neoplasms

NCT number NCT03599960
Study type Interventional
Source Centre Hospitalier Universitaire de Besancon
Contact
Status Active, not recruiting
Phase Phase 2
Start date May 2, 2019
Completion date November 2024

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05645744 - Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
Completed NCT02113982 - SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Phase 1/Phase 2
Active, not recruiting NCT04013685 - Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Phase 1
Terminated NCT03203369 - Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN Phase 1
Recruiting NCT05430971 - Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Terminated NCT04109482 - Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN. Phase 1/Phase 2
Recruiting NCT06006403 - Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm Phase 1/Phase 2